One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Jacob Halaska, ©Index Stock Imagery Researchers like mice. US government statistics reveal that the whiskered ones show up in 90% of all experiments. Mice come cheap, procreate often, and die fairly ...

A recent study confirms that people with Parkinson's disease have different gut microbiota compared with healthy individuals, suggesting that bacterial imbalance may play a role in this condition.

ProtGPS predicts protein localization, offering insights into function and disease. The AI model identifies mutations that alter localization, revealing potential disease mechanisms. Researchers ...

Liver disease researchers are hoping AI can improve their trial design. By Isabella Cueto April 7, 2023. ... Her focus includes autoimmune conditions and diseases of the lungs, kidneys, liver (and ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

CARLSBAD, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases ...

The research paper, “APOLLOE4 Phase 3 Study of Oral ALZ-801/Valiltramiprosate in APOE ε4/ε4 Homozygotes with Early Alzheimer’s Disease: Trial Design & Baseline Characteristics,” was ...

Shares of Design Therapeutics Inc. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia ...

BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025) ...

A new startup founded by a former Google DeepMind scientist is exiting stealth with $50 million in funding.. Latent Labs is building AI foundation models to “make biology programmable,” and it ...

A report on the researchers' proof-of-concept work on laboratory-cultured cells and mice appears in the March 11 issue of Molecular Therapy—Nucleic Acids and could pave the way for therapies for ...